CEL-SCI Corporation (CVM)

Oncology Corporate Profile

Stock Performance

0.5685
0.0049

HQ Location

8229 Boone Boulevard, Suite 802
Vienna, VA 22182

Company Description

CEL-SCI is dedicated to improving the treatment of cancer and other diseases by unleashing the power of the immune system; the body's natural and most potent defense system. The Company's flagship product, Multikine®, is the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. Multikine® is cleared for a phase III clinical trial for patients with head and neck cancers. Unlike typical immunotherapy drugs, Multikinea is the first of the class of immunotherapy treatments deemed Immune Simulators.Multikinea is multi-targeted; it is the only cancer immunotherapy that both kills cancer cells in a targeted fashion and activates the general immune system to destroy the cancer. CEL-SCI was founded in 1983.

Website: http://www.cel-sci.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Multikine®immunotherapy1st line metastatic Head & Neck cancerIII
Multikine®immunotherapyCervical cancerI

View additional information on product candidates here »

Source: http://www.cel-sci.com

Recent News Headlines

CEL-SCI Provides Update on Partial Clinical Hold on Phase 3 Clinical Trial

10/21/2016 05:04 pm

(Yahoo! Finance) Oct 21, 2016 - CEL-SCI Corporation announced today: following up on our press release issued on September 26, 2016, we have received the Partial Clinical Hold letter from the U.S. Food and Drug Administration (FDA). CEL-SCI has started working on a response to the FDA and will work diligently with the FDA to seek to have the partial clinical hold lifted.

Stock of Vienna-Based Cel-Sci Tumbles On FDA Notice

9/27/2016 03:49 pm

(WTOP-Radio [Washington, DC]) Sept 27, 2016 - Vienna, Virginia-based biotechnology company Cel-Sci, currently running late-stage clinical trials with patients for its head and neck cancer treatment, watched its stock fall more than 30 percent in early Tuesday trading after a notice from the Food and Drug Administration.

Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 in Metastatic Renal Cell Carcinoma Following Interim Data Review

6/13/2016 07:02 am

(Argos) June 13, 2016 - Argos Therapeutics Inc. today announced that the independent data monitoring committee (IDMC) for the Company’s pivotal Phase 3 ADAPT clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC) has recommended the continuation of the trial based on results of the IDMC’s scheduled interim data review.

Differences in Metabolism between Androgen-Dependent and Castration Resistant Prostate Cancer May Lead to New Therapies

5/26/2016 11:03 am

(Baylor College of Medicine) May 19, 2016 - Researchers from Baylor College of Medicine and University of Michigan, along with collaborators in other institutions, have determined that castration resistant prostate cancer (CRPC) has particular metabolic characteristics that may open new possibilities for treatment.

Scientists’ Work on DNA Repair Earns Nobel Prize in Chemistry

10/8/2015 06:05 am

(Wall Street Journal) Oct 7, 2015 - A trio of scientists was awarded the Nobel Prize in chemistry for describing how cells repair damaged DNA, breakthroughs that are helping to guide the development of new cancer drugs.

Hillary Clinton’s Health Care Proposals, Focused on Cost, Go Well Beyond Obama’s

10/7/2015 01:01 pm

(New York Times) Oct 6, 2015 - Mrs. Clinton appears to be more willing to confront insurers and drug makers over high prices, going beyond such measures in the Affordable Care Act.

Right-to-die Backers Say California Helps Fight Elsewhere

10/7/2015 12:03 pm

(Yahoo! News/Associated Press) Oct 6, 2015 - It will soon be legal for the terminally ill to end their own lives in the nation's most populous state, and right-to-die advocates expect other states to follow California's example.

Pricey New Cholesterol Rx Covered By Big Drug Plan, But…

10/7/2015 12:02 pm

(CNBC) Oct 6, 2015 - The nation's largest pharmacy benefits manager announced late Tuesday that it will include two new, very expensive cholesterol drugs on its list of covered drugs next year — but also has a plan to prevent the medications from busting budgets.

Final Stage 3 EHR Rule Is Out, But HHS Signals More Changes Ahead

10/7/2015 12:01 pm

(Modern Healthcare) Oct 6, 2015 - The Obama administration, under pressure from Congress and the healthcare industry to ease its mandates for the use of electronic health records, issued regulations for the current and final stages of its incentive program for the technology. But officials also acknowledged the new rules are almost guaranteed to be revised in the coming months.

FDA's New Anti-Smoking Campaign Uses Hip-Hop To Target Youth

10/7/2015 12:00 pm

(Associated Press/The Big Story) Oct 6, 2015 - Government health officials are betting they can adapt the sounds, style and swagger of hip-hop culture to discourage young African Americans, Hispanics and other minority youths from using tobacco.

Pa. Mandates 3-D Mammogram Coverage

10/7/2015 12:00 pm

(Philadelphia Inquirer) Oct 6, 2015 - Women in Pennsylvania who undergo breast cancer screening with the latest advance, three-dimensional mammography, will not be charged extra for it.

Buyer Beware: A Mammogram’s Price Can Vary By Nearly $1,000, Study Finds

10/7/2015 12:00 pm

(Kaiser Health News) Oct 7, 20145 - Thinking about getting a mammogram in the Dallas-Fort Worth area? You might check carefully because the cost can vary from $50 to as much as $1,045.

Altor Bioscience Announces NCI Phase II SBIR Grant Award and Publication Supporting Ongoing Clinical Trial of IL-15 Super Agonist ALT-803 in Combination with Anti-CD20 Antibody Therapy for Relapsed / Refractory Non-Hodgkin Lymphoma

10/7/2015 11:05 am

(Yahoo! Finance) Oct 6, 2015 - Altor BioScience Corporation announced today that it has been awarded a Small Business Innovation Research (SBIR) Direct-to-Phase II grant by the National Cancer Institute (NCI) to support an ongoing Phase 1/2 clinical trial of ALT-803 in combination with the approved therapeutic antibody (Ab) rituximab in patients with relapsed or refractory indolent B cell non-Hodgkin lymphoma (iNHL).

NCI’s Steven Rosenberg Wins Service to America Medal

10/7/2015 11:05 am

(NCI/Cancer Currents Blog) Oct 7, 2015 - The Partnership for Public Service has awarded Steven A. Rosenberg, M.D., chief of the Surgery Branch in NCI's Center for Cancer Research, with its highest 2015 Samuel J. Heyman Service to America Medal, or Sammie, for his research to develop life-saving immune-based therapies for patients with advanced cancers.

Myriad Genetics and Tufts Health Plan Sign Agreement to Cover Prolaris® for Members with Localized Prostate Cancer

10/7/2015 11:04 am

(Benzinga) Oct 7, 2015 – Myriad Genetics, Inc. today announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris® for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy test validated against prostate cancer specific mortality.

Patient Wins High Court Challenge Against Company's Cancer Gene Patent

10/7/2015 11:04 am

(The Guardian/Australian Associated Press [UK]) Oct 6, 2015 - Yvonne D’Arcy took US-based biotech company Myriad Genetics to court over its patent of the BRCA1 gene linked to breast and ovarian cancer.

Invitae Expands Its Hereditary Cancer Offering

10/7/2015 11:04 am

(Yahoo! Finance) Oct 7, 2015 - Now offering new high quality panels for gastric cancer, for common hereditary cancer, and for expanded breast, breast and gynecologic, colon, and pancreatic cancer testing.

N-of-One Launches PrecisionInsights™ for Cost Effective, Quality Clinical Interpretation of 15-20 Gene NGS Solid Tumor Panels

10/7/2015 11:04 am

(Pharmiweb.com) Oct 6, 2015 - N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced N-of-One PrecisionInsights™, a new clinical interpretation solution specifically designed for small gene panels of 15-20 genes.

Astex Pharmaceuticals Announces Orphan Drug Designation for Guadecitabine (SGI-110) in the Treatment of Acute Myeloid Leukemia

10/7/2015 11:04 am

(Yahoo! Finance) Oct 6, 2015 - Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced today that its novel hypomethylating agent, guadecitabine (SGI-110), has been granted an orphan drug designation by the US FDA.

Ergomed Increases Its Co-Development Contribution up to $12,000,000 in CEL-SCI’s Phase 3 Head and Neck Cancer Trial

10/5/2015 04:03 pm

(TheStreet) Oct 5, 2015 - CEL-SCI Corporation and its Clinical Research Organization (CRO) Ergomed plc today announced that they have expanded their co-development agreement with increased activities to be undertaken by Ergomed.

Britain Begins Review to Speed Access to New Drugs

11/20/2014 05:02 am

(Reuters) Nov 20, 2014 - The British government has launched a review to speed the path to market for new drugs and medical devices in an attempt to improve patient care and make the country a more attractive place for investment in life sciences.

Cel-Sci's Enrollment Math Doesn't Add Up

8/1/2014 05:26 pm

(TheStreet) Aug 1, 2014 - In order to enroll the remaining 648 patients into the Multikine study by the end of 2015, Cel-Sci needs to average 40.5 patients per month, or 121.5 patients per quarter.

Cel-Sci's Enrollment Math Doesn't Add Up

8/1/2014 07:02 am

(TheStreet) Aug 1, 2014 - In order to enroll the remaining 648 patients into the Multikine study by the end of 2015, Cel-Sci needs to average 40.5 patients per month, or 121.5 patients per quarter.

Arizona Cancer Research Alliance & 21st Century Oncology to Enroll Patients in CEL-SCI's Global Phase III Head and Neck Cancer Trial

4/2/2014 05:26 pm

(TheStreet) Apr 1, 2014 - CEL-SCI Corporation today announced it has expanded its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in the U.S. with the addition of a new site in Scottsdale, Arizona.

Arizona Cancer Research Alliance & 21st Century Oncology to Enroll Patients in CEL-SCI's Global Phase III Head and Neck Cancer Trial

4/2/2014 12:02 pm

(TheStreet) Apr 1, 2014 - CEL-SCI Corporation today announced it has expanded its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in the U.S. with the addition of a new site in Scottsdale, Arizona.

First U.S. Clinical Site Opens for CEL-SCI’s Global Phase III Immunotherapy Head and Neck Cancer Trial Expansion

3/4/2014 06:03 pm

(4-traders) Mar 4, 2014 - Ten to 15 U.S. centers planned for American cancer patients to enroll in the world’s largest clinical trial for the treatment of head and neck cancer.

First U.S. Clinical Site Opens for CEL-SCI’s Global Phase III Immunotherapy Head and Neck Cancer Trial Expansion

3/4/2014 12:00 pm

(4-traders) Mar 4, 2014 - Ten to 15 U.S. centers planned for American cancer patients to enroll in the world’s largest clinical trial for the treatment of head and neck cancer.

CEL-SCI Corporation Announces IDMC Conclusions From Interim Review of Phase III Head and Neck Cancer Trial Data

11/5/2013 06:08 pm

(Yahoo! Finance) Nov 5, 2013 - Committee of prominent physicians and scientists affirms continuation of Phase III trial as scheduled; CEL-SCI is expanding study to more clinical sites to accelerate enrollment.

CEL-SCI Corporation Announces IDMC Conclusions From Interim Review of Phase III Head and Neck Cancer Trial Data

11/5/2013 12:00 pm

(Yahoo! Finance) Nov 5, 2013 - Committee of prominent physicians and scientists affirms continuation of Phase III trial as scheduled; CEL-SCI is expanding study to more clinical sites to accelerate enrollment.

West Clinic Researchers Present Findings at 2013 American Society for Clinical Oncology (ASCO) Meeting

6/1/2013 07:02 pm

(Sacramento Bee) May 31, 2013 - The West Clinic, the Mid-South's premier cancer center and world-class center of excellence in medical oncology, hematology, oncologic imaging, clinical research and other advanced medical care, announced today five of its physician-researchers will participate in ten presentations at ASCO.

Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail!

4/26/2013 04:59 pm

(The Street) Apr 26, 2013 - Here are some highlights from the upcoming ASCO annual meeting based on my first, quick look through the abstracts:

Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail!

4/26/2013 11:05 am

(The Street) Apr 26, 2013 - Here are some highlights from the upcoming ASCO annual meeting based on my first, quick look through the abstracts:

CEL-SCI and Northeast Ohio Medical University Develop Novel Cancer Vaccine That Prevents and Treats Breast Cancer

1/31/2013 06:44 pm

(4-traders) Jan 31, 2013 - CEL-SCI Corporation announced that its longstanding collaboration with Northeast Ohio Medical University has produced a new investigational breast cancer vaccine which prevents and treats a HER-2/neu expressing breast cancer tumor in a mouse model of the disease.

CEL-SCI and Northeast Ohio Medical University Develop Novel Cancer Vaccine That Prevents and Treats Breast Cancer

1/31/2013 12:04 pm

(4-traders) Jan 31, 2013 - CEL-SCI Corporation announced that its longstanding collaboration with Northeast Ohio Medical University has produced a new investigational breast cancer vaccine which prevents and treats a HER-2/neu expressing breast cancer tumor in a mouse model of the disease.